Flexion Therapeutics Stock News

After the company reported it had priced its common share offering at $9.75 per share, shares in Flexion Therapeutics (NASDAQ: FLXN) are trading 10% lower at 11:30 a.m. EST on Thursday. Demand for t

Flexion Therapeutics, Inc. (FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceed

Alnylam and Pfizer to discuss how innovative oncology and specialty medicines are transforming commercial models and helping improve patients' lives

Flexion Therapeutics, Inc. (FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a

Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

BURLINGTON, Mass., May 13, 2020 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.

This is Scott Young, Vice President of Corporate Communications and Investor Relations. Today's conference call will be led by Flexion's Chief Executive Officer, Dr. Michael Clayman; and he is joined

Q1 2020 Flexion Therapeutics Inc Earnings Call

Australia's performing arts scene faces an existential crisis that philanthropy alone can't solve, say three chairmen of Australia's major companies.